| Identification | Back Directory | [Name]
SENAZODAN | [CAS]
98326-32-0 | [Synonyms]
SENAZODAN
Unii-427L2I2kim
6-(4-(4-Pyridinylamino)phenyl)-4,5-dihydro-3(2H)-pyridazinone
3-[4-(pyridin-4-ylamino)phenyl]-4,5-dihydro-1H-pyridazin-6-one
3(2H)-Pyridazinone, 4,5-dihydro-6-(4-(4-pyridinylamino)phenyl)- | [Molecular Formula]
C15H14N4O | [MDL Number]
MFCD01758407 | [MOL File]
98326-32-0.mol | [Molecular Weight]
266.3 |
| Hazard Information | Back Directory | [Uses]
Senazodan (MCI 154) is a Ca2+ sensitiser, and also shows inhibition effect on PDE III[1][2]. | [in vivo]
Senazodan (0.1~2.0 mg/kg; left femoral vein catheterization infusion) decreases the pressor effect of norepinephrine (NE)[3].
Senazodan (0.1 mg/kg; i.v.) makes LVSP, IP, MC, and Lo all increased significantly, while heart rate is not obviously changed and left ventricular end-diastolic pressure (LVEDP) is reduced remarkably[4]. | Animal Model: | Wistar rats (200~250 g)[3] | | Dosage: | 0.1~2.0 mg/kg | | Administration: | Left femoral vein catheterization infusion | | Result: | Decreased the pressor effect of norepinephrine (NE).
|
| Animal Model: | Rabbits[4] | | Dosage: | 0.1 mg/kg | | Administration: | I.v. | | Result: | LVSP, IP, MC, and Lo all were increased significantly while heart rate was not obviously changed and left ventricular end-diastolic pressure (LVEDP) was reduced remarkably.
|
| [References]
[1] Lehtonen LA, et al. Pharmacokinetics and pharmacodynamics of intravenous inotropic agents. Clin Pharmacokinet. 2004;43(3):187-203. DOI:10.2165/00003088-200443030-00003
[2] Erhardt L. An emerging role for calcium sensitisation in the treatment of heart failure. Expert Opin Investig Drugs. 2005 Jun;14(6):659-70. DOI:10.1517/13543784.14.6.659
[3] Yang G, et al. Effects of MCI-154 on vascular reactivity and its mechanisms after hemorrhagic shock in rats. J Cardiovasc Pharmacol. 2006;47(6):751-757. DOI:10.1097/01.fjc.0000211790.14787.e7
[4] Ming MJ, et al. Effects of MCI-154, a calcium sensitizer, on cardiac dysfunction in endotoxic shock in rabbits. Shock. 2000;13(6):459-463. DOI:10.1097/00024382-200006000-00007 |
|
| Company Name: |
MedChemExpress
|
| Tel: |
021-58955995 |
| Website: |
www.medchemexpress.com |
|